Tikva Allocell is a cell therapy company focused on a Second Generation Allogeneic EBV-Specific T cell (ALLO EBVST) platform to target difficult-to-treat cancers.
At Tikva Allocell, our mission is to develop safe, effective, readily available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of ALLO EBVST and proprietary technologies that enhance the T cell's performance to treat cancer.
Company Details
- Employees
- 11
- Founded
- 2023
- Address
- 61 Biopolis Drive, #03-09,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://tikvaallocell.com/
- HQ
- Biopolis, Singapore
Tikva Allocell Pte Ltd Questions
Tikva Allocell Pte Ltd's website is https://tikvaallocell.com/
Tikva Allocell Pte Ltd's LinkedIn profile is https://sg.linkedin.com/company/tikva-allocell-pte-ltd
Tikva Allocell Pte Ltd has
11 employees.
View email and phone details for 11
employees at Tikva Allocell Pte Ltd.
Tikva Allocell Pte Ltd's industry is
Biotechnology Research
Tikva Allocell Pte Ltd's top competitors are
Immunoscape,
Clavystbio,
Biosyngen,
Mirxes,
Scg Cell Therapy,
Nsg Biolabs,
Nuevocor,
Tessa Therapeutics Ltd,
Engine Biosciences,
Hummingbird Bioscience.
Tikva Allocell Pte Ltd's categories are Biotechnology Research
Tikva Allocell Pte Ltd's founding year is 2023
